Efficacy of rituximab in refractory polymyositis.

Abstract	We describe the effectiveness of rituximab, an anti-B lymphocyte monoclonal antibody, in a case of refractory polymyositis with interstitial pulmonary disease and anti-Jo-1 autoantibody (antisynthetase syndrome). Rituximab was well tolerated, and its efficacy in inflammatory myositis should be evaluated.
Authors	Olivier Lambotte, Rami Kotb, Gwenola Maigne, François-Xavier Blanc, Cécile Goujard, Jean François Delfraissy
Journal	The Journal of rheumatology (J Rheumatol) Vol. 32 Issue 7 Pg. 1369-70 (Jul 2005) ISSN: 0315-162X [Print] Canada
PMID	15996082 (Publication Type: Case Reports, Journal Article)
Chemical References	Antibodies, Antinuclear Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Immunologic Factors Jo-1 antibody Rituximab
Topics	Antibodies, Antinuclear (blood) Antibodies, Monoclonal (administration & dosage) Antibodies, Monoclonal, Murine-Derived Drug Resistance Female Humans Immunologic Factors (administration & dosage) Middle Aged Polymyositis (drug therapy, immunology) Rituximab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!